CRL vs KNSA · rev $2.00B vs P/E 53, rev $677.6M
Charles River Laboratories (CRL) versus Kiniksa Pharmaceuticals Ltd (KNSA) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Kiniksa Pharmaceuticals Ltd (KNSA) is a drug manufacturers - specialty & generic company listed on US.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported KNSA revenue for 2025-12-31 was $677.6M. Net income was $59.0M. Revenue was up 60.1% from 2024-12-31 to 2025-12-31. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
CRL currently screens at market cap $7.78B. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
Not investment advice. Open the CRL and KNSA stock pages for the full models.
Not investment advice.